| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
GenNBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩389.00 |
| 52 Week High | ₩1,164.00 |
| 52 Week Low | ₩352.00 |
| Beta | 0.82 |
| 1 Month Change | 0% |
| 3 Month Change | -17.93% |
| 1 Year Change | -65.58% |
| 3 Year Change | -96.27% |
| 5 Year Change | -95.87% |
| Change since IPO | -98.81% |
Recent News & Updates
Shareholder Returns
| A072520 | KR Healthcare | KR Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 2.2% |
| 1Y | -65.6% | 18.6% | 5.4% |
Return vs Industry: A072520 underperformed the KR Healthcare industry which returned 21% over the past year.
Return vs Market: A072520 underperformed the KR Market which returned 4.5% over the past year.
Price Volatility
| A072520 volatility | |
|---|---|
| A072520 Average Weekly Movement | 7.8% |
| Healthcare Industry Average Movement | 5.7% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A072520's share price has been volatile over the past 3 months.
Volatility Over Time: A072520's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 76 | n/a | www.gennbio.com |
GenNBio Inc. operates in the bio industry in South Korea. It engages in the research and development of xenogeneic organs; conducts non-clinical trial service on primates and rodents; development of artificial organs and new drugs; and is involved in pharmaceutical and medical device distribution business; as well as operates a transplant hospital. The company also offers xenotransplantation process, which is transplanting cells, organs, tissues, etc. from animals to humans.
GenNBio Inc. Fundamentals Summary
| A072520 fundamental statistics | |
|---|---|
| Market cap | ₩28.84b |
| Earnings (TTM) | -₩15.67b |
| Revenue (TTM) | ₩5.29b |
5.5x
P/S Ratio-1.8x
P/E RatioIs A072520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A072520 income statement (TTM) | |
|---|---|
| Revenue | ₩5.29b |
| Cost of Revenue | ₩4.66b |
| Gross Profit | ₩625.24m |
| Other Expenses | ₩16.29b |
| Earnings | -₩15.67b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -211.36 |
| Gross Margin | 11.82% |
| Net Profit Margin | -296.28% |
| Debt/Equity Ratio | 40.7% |
How did A072520 perform over the long term?
See historical performance and comparison